Progress and prospects for herpesvirus vaccination using gB antigens
By
Solomon English
Adam Khan-Qureshi
Alexander D. Douglas
May 29, 2026
Clinical Scorecard: Advancements and Future Directions in Herpesvirus Vaccination Targeting gB Antigens
At a Glance
Category Detail
Condition Herpesvirus infections Key Mechanisms Targeting glycoprotein B (gB) for vaccine development Target Population Individuals at risk for herpesvirus infections, including EBV, HCMV, HSV-1, and HSV-2 Care Setting Clinical trials and vaccine development
Key Highlights
gB is a conserved fusogen across herpesviruses, crucial for cell entry. Current vaccines against VZV demonstrate the potential for high efficacy. gB-targeting vaccines have shown partial efficacy in clinical trials for HCMV. There is a significant unmet need for vaccines against EBV, HCMV, and HSV. Recent advances focus on stabilizing the pre-fusion conformation of gB. Guideline-Based Recommendations
Diagnosis
Identify herpesvirus infections through serological and molecular methods. Management
Consider gB-based vaccines in clinical trials for herpesvirus prevention. Monitoring & Follow-up
Evaluate immune responses to gB in vaccine trials. Risks
Assess potential adverse effects of gB-targeting vaccines. Patient & Prescribing Data
Individuals at risk for herpesvirus-related diseases.
gB-based vaccines are in development, with varying efficacy outcomes.
Clinical Best Practices
Focus on the immunological protection offered by gB-targeting vaccines. Utilize insights from in vitro studies on antibody-gB interactions. Monitor advancements in vaccine formulations and gB stabilization techniques. Related Resources & Content
